Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis

Phase 2/3 Unknown 30 enrolled University of Aarhus

RandomizedCrossoverDouble-blindTreatment

Summary

This study examines the effect of adjuvant therapy with the oral beta-agonist Salbutamol in patients with generalized myasthenia gravis on stable standard of care having residual symptoms.

Timeline

Start: 2019-04-01
Primary completion: 2021-10-31
Completion: 2021-10-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Salbutamol	Unknown	4 mg	Oral

Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis

Summary

Timeline

Drugs

Indications